Fenwick & West represented Cardiac Dimensions Pty. Ltd., a leader in the development of innovative, minimally invasive treatments for patients with heart failure, in its $39 million Series B financing. The round includes new investor Australia-based Hostplus and venture debt from Oxford Finance LLC, including support from existing investors M.H, Carnegie & Co., Arboretum Ventures, Lumira Capital, LSP Health Economics Fund and Aperture Venture Partners.
Cardiac Dimensions will use the funding to build clinical evidence for Cardiac Dimensions’ Carillon® Mitral Contour System® for the treatment of functional mitral regurgitation (FMR) in patients with heart failure. More information about Cardiac Dimensions’ $39 million Series B financing can be obtained from the company press release.
The Fenwick transaction team was led by corporate lawyers Andrew Albertson and Amy Zhang.